These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 23074173)

  • 1. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
    Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
    Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase.
    Kim JL; Kang HN; Kang MH; Yoo YA; Kim JS; Choi CW
    Acta Haematol; 2011; 126(4):241-5. PubMed ID: 21951998
    [No Abstract]   [Full Text] [Related]  

  • 3. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
    Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
    Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.
    Ford SJ; Obeidy P; Lovejoy DB; Bedford M; Nichols L; Chadwick C; Tucker O; Lui GY; Kalinowski DS; Jansson PJ; Iqbal TH; Alderson D; Richardson DR; Tselepis C
    Br J Pharmacol; 2013 Mar; 168(6):1316-28. PubMed ID: 23126308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
    Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
    BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of deferasirox as a novel therapeutic modality in gastric cancer.
    Choi JH; Kim JS; Won YW; Uhm J; Park BB; Lee YY
    World J Surg Oncol; 2016 Mar; 14():77. PubMed ID: 26965928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer.
    Kovacevic Z; Chikhani S; Lovejoy DB; Richardson DR
    Mol Pharmacol; 2011 Oct; 80(4):598-609. PubMed ID: 21719465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Iron Chelator, Dp44mT, Effectively Inhibits Human Oral Squamous Cell Carcinoma Cell Growth in Vitro and in Vivo.
    Lee JC; Chiang KC; Feng TH; Chen YJ; Chuang ST; Tsui KH; Chung LC; Juang HH
    Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27589737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation.
    Le NT; Richardson DR
    Carcinogenesis; 2003 Jun; 24(6):1045-58. PubMed ID: 12807743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
    Chaston TB; Lovejoy DB; Watts RN; Richardson DR
    Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.
    Vazana-Barad L; Granot G; Mor-Tzuntz R; Levi I; Dreyling M; Nathan I; Shpilberg O
    Leuk Lymphoma; 2013 Apr; 54(4):851-9. PubMed ID: 23020673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron chelation in the treatment of cancer: a new role for deferasirox?
    Bedford MR; Ford SJ; Horniblow RD; Iqbal TH; Tselepis C
    J Clin Pharmacol; 2013 Sep; 53(9):885-91. PubMed ID: 23740857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.
    Gaboriau F; Leray AM; Ropert M; Gouffier L; Cannie I; Troadec MB; Loréal O; Brissot P; Lescoat G
    Biometals; 2010 Apr; 23(2):231-45. PubMed ID: 19997770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE; Hagemann TM
    Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, characterization and in vitro anticancer evaluations of two novel derivatives of deferasirox iron chelator.
    Salehi S; Saljooghi ASh; Shiri A
    Eur J Pharmacol; 2016 Jun; 781():209-17. PubMed ID: 27090924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.
    Nick H; Allegrini PR; Fozard L; Junker U; Rojkjaer L; Salie R; Niederkofler V; O'Reilly T
    Exp Biol Med (Maywood); 2009 May; 234(5):492-503. PubMed ID: 19234060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
    Patel V; Lahusen T; Leethanakul C; Igishi T; Kremer M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS; Senderowicz AM
    Clin Cancer Res; 2002 Nov; 8(11):3549-60. PubMed ID: 12429646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferasirox: the new oral iron chelator.
    Dubey AP; Sudha S; Parakh A
    Indian Pediatr; 2007 Aug; 44(8):603-7. PubMed ID: 17827637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhabdoid tumor growth is inhibited by flavopiridol.
    Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV
    Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron-induced cardiac damage: role of apoptosis and deferasirox intervention.
    Wang Y; Wu M; Al-Rousan R; Liu H; Fannin J; Paturi S; Arvapalli RK; Katta A; Kakarla SK; Rice KM; Triest WE; Blough ER
    J Pharmacol Exp Ther; 2011 Jan; 336(1):56-63. PubMed ID: 20947636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.